The effect of darapladib administration to inflammation marker in early development of atherosclerosis: in vivo study for dyslipidemia model

Dyslipidemia is a chronic inflammation condition which related to Lp-PLA2. LpPLA2 has an anti-inflammatory role as it hydrolyze atherogenesis mediators. This mediators, such as oxLDL to produces lysophosphatidylcholine (lysoPC) and oxidized fatty acid (oxFA) that have pro-inflammatory, proliferative and pro-atherogenic effect. This study aimed to discover the expression of inflammation marker of dyslipidemia in vivo model with darapladib treatment. A true experimental laboratory and only posttest with control group design used 30 Spraque Dawley rats which were divided into three main groups: normal, dyslipidemia, and dyslipidemia with darapladib administration. Each group consisted of two serials treatment time: 8-weeks and 16-weeks. Parameter measured was ox-LDL level, TNF-α, iNOS, IL-6, PAF and PAT thickness and also lipid profile. The study results analyzed using ANOVA test showed that darapladib were significantly (p <0.05) lowering expression of Ox-LDL in aortic tissue, blood Ox-LDL and IL-6 in vivo model of dyslipidemia. This study concludes that dalapladib proved to have role to decrease Ox-LDL in aortic tissue, blood Ox-LDL and IL-6 significantly in vivo model of dyslipidemia.